A combination of three biomarkers accurately predicted abnormal accumulation of beta-amyloid plaques in the brains of living Alzheimer's disease patients.
The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
